GO:0004925 prolactin receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004925 (prolactin receptor activity) is a molecular function defined as combining with prolactin and transmitting the signal across the membrane to initiate a change in cell activity.
• The prolactin receptor (PRLR) is a single-pass transmembrane cytokine receptor that signals mainly through JAK2/STAT5, and also engages MAPK, PI3K/AKT and SRC-family pathways.
• PRLR signaling drives mammary gland development, lactation, reproduction and metabolic homeostasis, and is dysregulated in breast cancer and other malignancies.
• PRLR levels and activity are controlled transcriptionally, by receptor shedding and trafficking, and by negative-feedback regulators, making the pathway druggable.
• Anti-PRLR strategies, including antagonists and antibody-drug conjugates, are under preclinical and clinical development for PRLR-positive tumors.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal dissection of PRLR signaling in disease and normal physiology.
Description
Prolactin receptor activity (GO:0004925) is the molecular function of binding the hormone prolactin and converting that binding event into an intracellular signal that changes cell behavior. It is the defining activity of the prolactin receptor (PRLR), a cytokine-receptor-family protein that is best known for its roles in mammary gland development, lactation and reproduction, but which also influences metabolism, immune function and tumor biology. Because the receptor sits at the interface between an endocrine hormone and multiple intracellular signaling cascades, its activity is a central node for both physiological and pathological research. At the molecular level, prolactin binding promotes receptor dimerization and activation of receptor-associated kinases, most prominently JAK2, which phosphorylates STAT5 and other substrates to reprogram gene expression. The same receptor can also couple to MAPK, PI3K/AKT and SRC-family pathways, which explains the pleiotropic effects of prolactin across tissues. Researchers study GO:0004925 to understand how a single ligand-receptor interaction produces context-dependent outputs, and to identify vulnerabilities in diseases where PRLR signaling is amplified. This article summarizes the authoritative definition of GO:0004925, the genes and proteins that execute it, the mechanisms that regulate it, its links to human disease, and the experimental and CRISPR-based methods used to interrogate it. All statements are grounded in the verified literature cited by number-.
prolactin receptor activity At A Glance
| GO ID | GO:0004925 |
|---|---|
| GO term | prolactin receptor activity |
| Ontology | molecular_function |
| Synonym | none listed |
| Definition | Combining with prolactin and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity |
| Major function | Binds prolactin and initiates intracellular signaling, principally through JAK2/STAT5, to alter gene expression and cell behavior |
| Representative receptor | PRLR (prolactin receptor), a single-pass transmembrane cytokine receptor |
| Primary ligand | Prolactin (PRL), a pituitary and extrapituitary hormone |
| Downstream pathways | JAK2/STAT5, MAPK/ERK, PI3K/AKT and SRC-family kinases |
| Disease relevance | Breast cancer, other PRLR-positive tumors and endocrine/metabolic disorders |
What Is GO:0004925?
In plain terms, GO:0004925 describes the job of a receptor that catches the hormone prolactin on the outside of the cell and passes a signal to the inside, causing the cell to change what it is doing. The QuickGO definition states that this activity involves combining with prolactin and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. It is a molecular function, not a process or a location, and it is executed by the prolactin receptor (PRLR) and its signaling partners.
Why Is prolactin receptor activity Important in Cell Biology?
GO:0004925 matters because prolactin receptor activity is a master switch for lactation and mammary development, a regulator of reproduction and metabolism, and a driver of oncogenic signaling in breast cancer and other tumors. Because the receptor is accessible on the cell surface and its activity can be blocked by antagonists or antibodies, it is also a tractable therapeutic target, with anti-PRLR antibody-drug conjugates and superactive antagonists advancing through preclinical development. Understanding the precise molecular function of PRLR is therefore essential for both basic endocrinology and translational oncology.
• Controls mammary gland development and lactation, making it central to reproductive biology.
• Regulates ovarian function, corpus luteum maintenance and fertility.
• Contributes to metabolic homeostasis and energy balance.
• Is overexpressed or hyperactive in a subset of breast cancers, where it promotes proliferation and survival.
• Supports PRLR-positive tumor growth, providing a rationale for anti-PRLR therapies.
• Can be targeted by receptor antagonists that block prolactin-driven signaling.
• Antibody-drug conjugates against PRLR show preclinical activity in PRLR-positive breast cancers.
• Receptor levels are dynamically regulated, affecting sensitivity to prolactin and to drugs.
• Serves as a model for cytokine receptor activation and JAK/STAT signaling.
• Provides a druggable node for endocrine and oncologic drug discovery.
Molecular Mechanism of prolactin receptor activity
Ligand binding and receptor dimerization
In simple terms: Prolactin grabs two receptor molecules and pulls them together, which switches the receptor on.
Prolactin receptor activity begins when prolactin binds the extracellular domain of PRLR, promoting receptor dimerization and conformational changes that activate the intracellular portion of the receptor. This ligand-induced assembly is the first step in transmitting the signal across the membrane.
JAK2 activation and STAT5 phosphorylation
In simple terms: Once the receptors are together, an enzyme called JAK2 tags STAT5, which then moves to the nucleus to turn genes on.
Dimerized PRLR recruits and activates JAK2, which phosphorylates tyrosine residues on the receptor and on STAT5. Phosphorylated STAT5 dimerizes, translocates to the nucleus and regulates transcription of prolactin-responsive genes, a hallmark of PRLR activity.
Non-STAT signaling branches
In simple terms: The receptor also sends signals through other routes, not just STAT5.
In addition to JAK2/STAT5, prolactin receptor activity engages MAPK/ERK, PI3K/AKT and SRC-family kinase pathways, which contribute to proliferation, survival and cytoskeletal changes. These branches help explain the tissue-specific and context-dependent effects of prolactin.
Receptor internalization and negative feedback
In simple terms: After signaling, the receptor is pulled inside the cell or shut down so the signal does not stay on forever.
Activated PRLR is internalized and trafficked through endosomal compartments, and negative-feedback regulators such as SOCS proteins dampen JAK2/STAT5 signaling. Regulation of receptor levels and activity is critical for normal physiology and is altered in breast cancer.
Transcriptional control of PRLR expression
In simple terms: The amount of receptor on the cell surface is controlled by how much PRLR gene is turned on.
PRLR gene transcription is controlled by multiple promoters and regulatory modalities that influence receptor abundance and isoform expression, with relevance to breast cancer resistance and invasiveness. Changes in receptor levels directly affect the magnitude of prolactin receptor activity.
Key Genes Involved in GO:0004925 prolactin receptor activity
The following genes and proteins are the principal executors and regulators of prolactin receptor activity (GO:0004925) and its downstream signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRLR | Encodes the prolactin receptor that binds prolactin and initiates signaling | Core receptor for GO:0004925; target for knockout, knock-in and overexpression studies |
| PRL | Encodes prolactin, the ligand that activates PRLR | Ligand for receptor activation assays and antagonist development |
| JAK2 | Tyrosine kinase that associates with PRLR and phosphorylates STAT5 | Key signaling node; mutation or inhibition alters PRLR output |
| STAT5A | Transcription factor activated downstream of PRLR | Readout of PRLR activity; knockout models reveal gene targets |
| STAT5B | Transcription factor activated downstream of PRLR | Contributes to prolactin-responsive gene expression |
| SOCS1 | Negative regulator of cytokine receptor signaling | Modulates duration of PRLR signaling |
| SOCS3 | Negative regulator of JAK/STAT signaling | Feedback control of prolactin receptor activity |
| SRC | Kinase contributing to non-STAT PRLR signaling | Studied for proliferative and migratory effects |
| MAPK1 | Effector kinase in the MAPK branch of PRLR signaling | Readout of non-STAT pathway activation |
| AKT1 | Kinase in the PI3K/AKT branch of PRLR signaling | Linked to survival signaling in PRLR-positive cells |
| ESR1 | Estrogen receptor that cross-talks with PRLR signaling | Relevant to breast cancer resistance mechanisms |
| ERBB2 | Receptor tyrosine kinase that can cooperate with PRLR | Context for combination targeting in breast cancer |
| FOXA1 | Transcription factor influencing hormone receptor biology | Potential modifier of PRLR transcriptional programs |
| GATA3 | Transcription factor in mammary development | Relevant to PRLR-driven differentiation |
| CCND1 | Cell cycle regulator downstream of prolactin signaling | Proliferation readout in PRLR studies |
| BCL2 | Anti-apoptotic protein influenced by prolactin signaling | Survival readout in PRLR-positive models |
| CDK4 | Cell cycle kinase linked to proliferative signaling | Target for combination studies with anti-PRLR agents |
| CDK6 | Cell cycle kinase linked to proliferative signaling | Target for combination studies with anti-PRLR agents |
How Is prolactin receptor activity Regulated?
Prolactin receptor activity is regulated at multiple levels. Transcription of PRLR is controlled by multiple promoters and regulatory modalities that determine receptor abundance and isoform usage, which is relevant to breast cancer resistance and invasiveness. Receptor protein levels and activity are further controlled by trafficking, internalization and shedding, and by negative-feedback proteins such as SOCS family members that dampen JAK2/STAT5 signaling. Because these regulatory layers set the sensitivity of cells to prolactin, they are important determinants of both normal physiology and tumor behavior.
prolactin receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PRLR | Breast cancer proliferation and survival | PRLR knockout and overexpression breast cancer cell lines |
| PRLR | Endocrine and reproductive dysfunction | PRLR point-mutation and knock-in models |
| PRL | Prolactin-driven signaling in tumors | PRL overexpression or knockout models |
| STAT5A | Transcription of prolactin-responsive genes | STAT5A knockout and reporter assays |
| JAK2 | Cytokine signaling in cancer | JAK2 point-mutation and inhibitor studies |
Breast cancer
PRLR is expressed in a large fraction of breast cancers, where prolactin receptor activity promotes proliferation, survival and differentiation programs. Regulation of PRLR levels and activity is altered in breast cancer and has been linked to resistance and invasiveness. Anti-PRLR strategies, including antibody-drug conjugates, show preclinical activity in PRLR-positive breast cancers, supporting the receptor as a therapeutic target.
Endocrine and reproductive disorders
Because prolactin receptor activity is required for mammary gland development, lactation and corpus luteum function, perturbations in this pathway are relevant to reproductive and endocrine disorders. Prolactin receptor antagonists have been developed as tools to block receptor activity in experimental settings.
Other PRLR-positive malignancies
Beyond breast cancer, PRLR signaling has been explored as a target in other tumor types where the receptor is expressed, motivating the development of anti-PRLR therapeutics. Superactive prolactin receptor antagonists provide reagents to test the consequences of blocking this activity.
From prolactin receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PRLR loss abolish prolactin signaling? | PRLR knockout cell line |
| Which residues are required for JAK2 coupling? | PRLR point-mutation knock-in |
| How does a disease-associated PRLR variant behave? | Knock-in of the variant allele |
| Where is PRLR expressed and trafficked? | Tagged knock-in (e.g., fluorescent or epitope tag) |
| Does PRLR overexpression drive proliferation? | PRLR overexpression cell model |
| Can anti-PRLR agents block signaling? | PRLR-positive cells treated with antagonists or ADCs |
How to Study the prolactin receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | Phosphorylation of STAT5, JAK2, ERK, AKT | Pathway activation after prolactin stimulation |
| Luciferase reporter | STAT5-driven transcription | Screening for PRLR pathway modulators |
| RNA-seq | Global transcriptional changes | Defining PRLR-dependent gene programs |
| Co-immunoprecipitation | Receptor-kinase interactions | Mapping PRLR signaling complexes |
| Fluorescence imaging | Receptor localization and trafficking | Studying internalization and endosomal sorting |
| Flow cytometry | Cell surface PRLR levels | Quantifying receptor abundance |
| Antagonist/ADC assays | Growth inhibition and signaling blockade | Preclinical evaluation of anti-PRLR agents |
| CRISPR knockout | Loss-of-function phenotypes | Testing causal roles of PRLR and partners |
Transcriptional and signaling readouts
Because prolactin receptor activity converges on STAT5 and other transcription factors, luciferase reporters and quantitative PCR of prolactin-responsive genes are standard readouts. RNA-seq can define the transcriptional program downstream of PRLR activation or blockade.
Protein phosphorylation and interaction assays
Western blotting for phosphorylated STAT5, JAK2, ERK and AKT is used to monitor pathway activation after prolactin stimulation. Co-immunoprecipitation and proximity assays can detect receptor-kinase interactions.
Receptor localization and trafficking
Fluorescence imaging of tagged PRLR allows tracking of receptor internalization and endosomal trafficking, which are key regulatory steps. Surface biotinylation and flow cytometry quantify receptor levels at the plasma membrane.
Pharmacologic and antibody-based perturbation
Prolactin receptor antagonists and anti-PRLR antibody-drug conjugates are used to test the consequences of blocking receptor activity in cells and xenograft models. These tools complement genetic approaches and inform therapeutic development.
How CRISPR Can Be Used to Study GO:0004925 prolactin receptor activity
Knockout
CRISPR knockout of PRLR or its signaling partners (for example JAK2 or STAT5A) removes prolactin receptor activity and reveals which downstream programs depend on it. Knockout cell lines are widely used to validate specificity of anti-PRLR agents.
Point Mutation
Point mutations in PRLR can be introduced to test which residues are required for JAK2 coupling, dimerization or trafficking, providing mechanistic insight into receptor activation. Such models help distinguish signaling branches and identify drug-resistance variants.
Knock-in
Knock-in of tagged or disease-associated PRLR alleles enables tracking of receptor localization and study of variant behavior in a native genomic context. This approach is valuable for linking genotype to receptor activity.
Overexpression
Overexpression of PRLR or its ligand prolactin can amplify signaling and model the receptor-high state seen in some tumors, supporting studies of proliferation and drug response. Overexpression models are also used to test antagonist potency.
How EDITGENE Supports prolactin receptor activity Research
Researchers studying prolactin receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, whether a specific variant alters receptor function, or whether a therapeutic strategy depends on PRLR expression. EDITGENE provides the CRISPR and cell-model toolkit to answer these questions with rigor.
Contact EDITGENE today to design your custom CRISPR model for prolactin receptor activity research.
Frequently Asked Questions About prolactin receptor activity
What is prolactin receptor activity (GO:0004925)?
It is the molecular function of binding prolactin and transmitting a signal across the membrane to change cell activity, executed by the prolactin receptor PRLR.
What genes are involved in prolactin receptor activity?
Key genes include PRLR, PRL, JAK2, STAT5A, STAT5B, SOCS1, SOCS3, SRC, MAPK1 and AKT1.
Which signaling pathways does the prolactin receptor activate?
PRLR activates JAK2/STAT5 as its principal pathway, and also engages MAPK/ERK, PI3K/AKT and SRC-family kinases.
Why is prolactin receptor activity important in breast cancer?
PRLR signaling promotes proliferation and survival in breast cancer, and receptor levels and activity are dysregulated in the disease.
Can prolactin receptor activity be blocked therapeutically?
Yes, prolactin receptor antagonists and anti-PRLR antibody-drug conjugates have shown preclinical activity in PRLR-positive cancers.
How is prolactin receptor activity regulated?
It is regulated by PRLR transcription, receptor trafficking and internalization, and negative-feedback proteins such as SOCS family members.
What experimental models are used to study prolactin receptor activity?
Common models include PRLR knockout, point-mutation, knock-in, tagged knock-in and overexpression cell lines, combined with signaling assays.
What methods measure prolactin receptor signaling?
Western blotting for phospho-STAT5, luciferase reporters, RNA-seq, co-immunoprecipitation, imaging and flow cytometry are widely used.
What is the role of JAK2 in prolactin receptor activity?
JAK2 is the tyrosine kinase recruited by activated PRLR that phosphorylates STAT5 and other substrates to propagate the signal.
How can CRISPR help study prolactin receptor activity?
CRISPR knockout, point mutation, knock-in and overexpression allow causal testing of PRLR and its partners in signaling and disease models.
Conclusion
Prolactin receptor activity (GO:0004925) is a well-defined molecular function that links the hormone prolactin to a network of intracellular signals controlling development, metabolism and tumor biology. Its principal JAK2/STAT5 axis, together with MAPK, PI3K/AKT and SRC branches, explains the pleiotropic effects of prolactin and provides multiple points for experimental and therapeutic intervention. Because PRLR signaling is dysregulated in breast cancer and is targetable by antagonists and antibody-drug conjugates, it remains an active area of translational research. CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with transcriptional, biochemical and imaging readouts, offer a rigorous path to dissect this pathway and to prioritize new therapeutic strategies.
References
- 1. Chasseloup F et al.. 2024. Prolactin: structure, receptors, and functions.. Rev Endocr Metab Disord 25(6):953-966 PMID: 39476210
- 2. Swaminathan G et al.. 2008. Regulation of prolactin receptor levels and activity in breast cancer.. J Mammary Gland Biol Neoplasia 13(1):81-91 PMID: 18204982
- 3. Kuo CB et al.. 1998. Prolactin receptor antagonists.. Endocrine 9(2):121-31 PMID: 9867245
- 4. Solomon G et al.. 2022. Preparation of Superactive Prolactin Receptor Antagonists.. Endocrinology 164(1) PMID: 36351045
- 5. Standing D et al.. 2022. Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies.. Front Endocrinol (Lausanne) 13:1112987 PMID: 36714582
- 6. Kelly MP et al.. 2017. Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers.. Mol Cancer Ther 16(7):1299-1311 PMID: 28377489
- 7. Kavarthapu R et al.. 2022. Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.. Front Endocrinol (Lausanne) 13:949396 PMID: 36187116
- 8. Brooks CL. 2012. Molecular mechanisms of prolactin and its receptor.. Endocr Rev 33(4):504-25 PMID: 22577091
